Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lymphoid Interstitial Pneumonia 1 Lip Neoplasms 1 Leukemia, Myeloid, Acute 1 Head and Neck Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 361 Pemetrexed 276 Cisplatin 230 Paclitaxel 213 Docetaxel 205 Gemcitabine 160 Erlotinib Hydrochloride 150 Bevacizumab 132 pembrolizumab 129 Radiotherapy 114 Nivolumab 88 durvalumab 84 Drug Therapy 84 osimertinib 82 atezolizumab 58 Vinorelbine 53 Gefitinib 53 Radiosurgery 50 Cetuximab 39 Taxes 37 130-nm albumin-bound paclitaxel 36 Ipilimumab 34 anlotinib 33 Surgical Procedures, Operative 33 Magnetic Resonance Spectroscopy 33 Etoposide 30 Albumin-Bound Paclitaxel 29 tislelizumab 27 icotinib 27 aflutinib 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Non-Small-Cell Lung × ficlatuzumab × Clear all

NCT02318368 2020-10-22

FOCAL

AVEO Pharmaceuticals, Inc.

Phase 2 Terminated

10 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡